Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.6K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

642
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
642
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.8K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

867
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
867
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response.

Therapeutic advances in psychopharmacology·2026
Same author

SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium-Treated Patients With Mood Disorders: A Real-World Historical Cohort Study.

Bipolar disorders·2026
Same author

Undermeasured and underused: Could a pharmacy accountability measure increase the use of clozapine?

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Question: Do GLP-1 and Dual GIP/GLP-1 Agonists Interact With Lithium, and What Are the Monitoring Implications?

Journal of clinical psychopharmacology·2026
Same author

Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.

The mental health clinician·2026
Same author

Effects of Parent-Coached Exposure Therapy Versus CBT on Avoidance, Impairment, and Remission in Childhood Anxiety.

Behavior therapy·2026

Related Experiment Video

Updated: Mar 1, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.7K

Concurrent Electroconvulsive Therapy and Bupropion Treatment.

Christopher R Takala1, Jonathan G Leung, Lauren L Murphy

  • 1From the Departments of *Psychiatry and Psychology and †Hospital Services, and ‡Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.

The Journal of ECT
|June 2, 2017
PubMed
Summary

Bupropion combined with electroconvulsive therapy (ECT) resulted in shorter seizure durations. However, the number of ECT treatments and risk of prolonged seizures did not significantly differ, warranting further investigation into psychotropic medication use with ECT.

More Related Videos

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

522

Related Experiment Videos

Last Updated: Mar 1, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.7K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

522

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Bupropion is known to lower the seizure threshold, increasing seizure risk dose-dependently.
  • Concomitant use of bupropion and electroconvulsive therapy (ECT) is controversial due to concerns about prolonged seizures.
  • This study systematically evaluates bupropion's impact on ECT treatment parameters.

Purpose of the Study:

  • To systematically evaluate the effect of concomitant bupropion use on electroconvulsive therapy (ECT) outcomes.
  • To compare seizure duration, number of treatments, and prolonged seizure risk between patients receiving ECT with and without bupropion.

Main Methods:

  • A retrospective analysis comparing a case group (n=119) receiving ECT with bupropion to a control group (n=261) receiving ECT alone.
  • Longitudinal mixed models and multivariable models were used to analyze seizure duration (EEG and motor) and the total number of treatments.
  • Covariates included age, gender, benzodiazepine use, lead placement, and setting.

Main Results:

  • Concomitant bupropion use with ECT resulted in significantly shorter motor seizure duration (P=0.047) and EEG seizure duration (P=0.001).
  • No significant differences were observed in the total number of ECT treatments (7.3 vs 7.0; P=0.23) or the probability of prolonged seizures (P=0.15).
  • Benzodiazepine use was more frequent in the control group (P=0.01).

Conclusions:

  • The study found that ECT with concomitant bupropion leads to shorter seizure durations without increasing the number of treatments or prolonged seizure risk.
  • Limitations include unavailable data on seizure threshold, ECT device type, bupropion specifics, and illness duration.
  • Further research is critical to re-evaluate the efficacy and safety of combining psychotropic medications like bupropion with ECT.